








key: cord-281948-xv7vuypd
authors: Hoang, Ansel; Chorath, Kevin; Moreira, Axel; Evans, Mary; Burmeister-Morton, Finn; Burmeister, Fiona; Naqvi, Rija; Petershack, Matthew; Moreira, Alvaro
title: COVID-19 in 7780 pediatric patients: A systematic review
date: 2020-06-26
journal: EClinicalMedicine
DOI: 10.1016/j.eclinm.2020.100433
sha: 
doc_id: 281948
cord_uid: xv7vuypd

BACKGROUND: Studies summarizing the clinical picture of COVID-19 in children are lacking. This review characterizes clinical symptoms, laboratory, and imaging findings, as well as therapies provided to confirmed pediatric cases of COVID-19. METHODS: Adhering to PRISMA guidelines, we searched four medical databases (PubMed, LitCovid, Scopus, WHO COVID-19 database) between December 1, 2019 to May 14, 2020 using the keywords “novel coronavirus”, “COVID-19” or “SARS-CoV-2”. We included published or in press peer-reviewed cross-sectional, case series, and case reports providing clinical signs, imaging findings, and/or laboratory results of pediatric patients who were positive for COVID-19. Risk of bias was appraised through the quality assessment tool published by the National Institutes of Health. PROSPERO registration # CRD42020182261. FINDINGS: We identified 131 studies across 26 countries comprising 7780 pediatric patients. Although fever (59·1%) and cough (55·9%) were the most frequent symptoms 19·3% of children were asymptomatic. Patchy lesions (21·0%) and ground-glass opacities (32·9%) depicted lung radiograph and computed tomography findings, respectively. Immunocompromised children or those with respiratory/cardiac disease comprised the largest subset of COVID-19 children with underlying medical conditions (152 of 233 individuals). Coinfections were observed in 5.6% of children and abnormal laboratory markers included serum D-dimer, procalcitonin, creatine kinase, and interleukin-6. Seven deaths were reported (0·09%) and 11 children (0·14%) met inclusion for multisystem inflammatory syndrome in children. INTERPRETATION: This review provides evidence that children diagnosed with COVID-19 have an overall excellent prognosis. Future longitudinal studies are needed to confirm our findings and better understand which patients are at increased risk for developing severe inflammation and multiorgan failure. FUNDING: Parker B. Francis and pilot grant from 2R25-HL126140. Funding agencies had no involvement in the study.

In December 2019, an unprecedented number of pneumonia cases presented in adult individuals from Wuhan, China [1] . Despite rapid action by the Chinese government and health officials, the number of similar presenting cases continued to rise at an alarming rate [2] . By January 2020 an emerging zoonotic agent, known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was identified in respiratory samples in patients diagnosed with pneumonia who subsequently developed respiratory failure [1] . The spread of SARS-CoV-2 from human to human, through respiratory droplets, has now resulted in a worldwide outbreak, now classified as a pandemic by the World Health Organization [3] .

As of June 3rd, 2020, there has been more than 6¢4 million confirmed cases worldwide and >380,000 fatalities [4] Most symptomatic cases have occurred in the adult population, characterized by fever, cough, malaise, and frequent hospitalization [1] . Accordingly, most of the published data is derived from adults with coronavirus disease 2019 (COVID- 19) who were hospitalized in China [5] . As the pandemic continues, we are now observing numerous reports describing the clinical presentation and hospital course of children with confirmed COVID-19 [5] .

What is currently known is that children have milder symptoms and are less likely to be hospitalized when compared to adults [6] . However, on May 14th, 2020 the United States Centers for Disease Control and Prevention (CDC) released a health advisory reporting a multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 [7] . This statement stemmed from a subset of pediatric patients manifesting with severe inflammation, multi-organ failure, and testing positive for SARS-CoV-2 [8, 9] .

Data extraction was performed by all investigators and compared by at least two investigators for consistency. Data collected included the type of article (e.g., case series), country of origin, number of pediatric patients, demographic information, and all clinical symptoms (e. g., fever, cough), laboratory values (e.g., CBC, LFTs, BMP), imaging studies (e.g., chest x-ray, CT, MRI), clinical outcomes (e.g., ICU admission), and treatments provided (e.g. antivirals).

The risk of bias for observational studies was appraised through the quality assessment tool published by the National Institutes of Health [10] . We opted to use this guide as the development of the assessment tool was conducted rigorously by researchers in the Agency for Healthcare Research and Quality Evidence-Based Practice Centers, the Cochrane Collaboration, the United States Preventive Services Task Force, the Scottish Intercollegiate Guidelines Network, the National Health Service Centre for Reviews and Disseminations, and consulting epidemiologists. Moreover, it was a preferred tool in a systematic review on risk of bias assessments used in PROSPERO-registered protocols [11] . Risk of bias was assessed independently by at least two investigators and disagreements were resolved by a third researcher (AM). Furthermore, the level of evidence was assessed according to Sackett [12] .

All laboratory data were converted to similar units and presented as mean with standard deviation (SD). Laboratory information presented as median (IQR) were converted to mean (SD), and denoted when unable to convert [13] . Publications that provided multiple timepoints (e.g., hospital course of individuals) for laboratory results were gathered and averaged. If the symptom was present anytime during the hospitalization, it was considered positive and characterized as a count with percent. A similar approach was taken for imaging information. Means, standard deviations, and proportion ratios were calculated using Microsoft Excel.

Statistical analyses between COVID-19 pediatric patients with/ without MIS-C was conducted on STATA v¢13. All statistical tests were two-sided, and significance was defined as a p value <0¢05. Continuous data was summarized as mean (standard deviation) or median (interquartile range) and assessed by Student's t-test or Wilcoxon rank sum. Categorical data was summarized as counts (percent) and analyzed by Fisher's exact test.

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

The search yielded 1,142 studies. After removing 237 duplicates, 905 articles were reviewed by abstract and title. After initial screening, only 319 articles met inclusion criteria and underwent full text evaluation. Publications that were retracted, or consisted of editorials, reviews, or commentaries that did not meet our criteria were removed, generating a final list of 131 articles (see Fig. 1 ).

Studies included in this review were published between January 24th to May 11th, 2020. Eight studies were cross sectional, 75 were case series, and 48 were case reports (refer to Table 1 ). Twenty-six countries were represented with the largest data derived from 2572 children from the United States. China comprised 64¢1% of the studies included in this review. Appendix 1 displays publications by the country of origin.

Twenty of the publications pertained to the neonatal population and the ages extended from an extremely premature neonate at 26 weeks gestation to 20 years of age. The level of evidence for all of the studies was 5 (1 is highest, 5 is lowest) and the risk of bias scores were between 2 to 7 (1 is lowest, 9 is highest, refer to Appendix 2).

A total of 7780 COVID-19 positive children were included. Fifty six percent of the individuals were male ( Table 2 ).

The mean age was 8¢9 years (SD 0¢5) and 75¢6% of patients were exposed to a family member who was diagnosed with COVID-19. The most common method for detection of the virus was through nasopharyngeal or throat swab (86¢5%). Need for intensive care unit observation or treatment was low (3¢3%). Twenty studies (n=655 individuals) reported an underlying medical condition; COVID-19 positive children who were immunosuppressed or had a history of a respiratory or cardiac condition comprised the majority (65¢%). Moreover, influenza and Mycoplasma were the most common co-infections (see Table 3 ). Table 4 summarizes clinical symptoms and imaging findings in COVID-19 confirmed pediatric patients. No symptoms were described in 456 of 2367 patients (19¢3%), while the two most common symptoms were fever (59¢1%), and cough (55¢9%). While upper respiratory symptoms were characteristic of COVID-19, some patients presented with mild or often overlooked symptoms such as fatigue, abdominal pain, or decreased appetite [14À16] . Table 4 also summates imaging findings. According to chest x-ray and computed tomography (CT), 23¢6% and 18¢9% had normal results, respectively. Patchy lesions were observed in 105 of 501 patients on chest radiography and bilateral ground glass opacities were the most frequent CT abnormality.

Complete blood counts were the most common laboratory results described (see Table 5 ). Overall, leukocytes were within normal values (7¢1 £ 10 3 /mL), whereas neutrophils were mildly decreased (44¢4%) while lymphocytes were marginally elevated (39¢9%). Markers of liver and renal function were normal. Four serum inflammatory markers were above the mean: D-dimer, procalcitonin, creatine kinase, and interleukin-6.

Sixty-six studies (n=614 individuals) provided information regarding treatments. Interferon was the most commonly administered drug (41¢0%), followed by empiric antibiotics (20¢2%). Of note, glucocorticoids, and intravenous immunoglobulin was used in 4¢1% and 3¢1% of patients, respectively. Complications we evaluated were rare and only described in 21 studies. There were 7 cases of kidney failure (0¢09%), 19 cases of shock (0¢24%), and 42 children were intubated (0¢54%). More details on treatments provided and complications can be found in Table 6 . Asymptomatic ( Abbreviations: ABG-arterial blood gas; ASA-aminosalicylate; ALT-alanine aminotransferase; AST-aspartate aminotransferase; BUN-blood urea nitrogen; BNP-brain natriuretic peptide; CBC-complete blood count; CK-creatine kinase; CPAP-continuous positive airway pressure; Cr-creatinine; CRP-C-reactive protein; CT-computed tomography; CXR-chest radiograph; ESR-erythrocyte sedimentation rate; Hgb-hemoglobin; Ig-immunoglobulin; IL-interleukin; IVIG-intravenous immunoglobulin; LDH-lactate dehydrogenase; LFTs-liver function tests; LUS-lung ultrasound; NK-natural killer cell; NR-not reported; PCT-procalcitonin; Plts-platelets; PT-prothrombin time; PTT-partial thromboplastin time; RSV-respiratory syncytial virus; TNF-tumor necrosis factor. *One patient met our inclusion, but the publication was a case series.

Eleven patients (0¢14%) met the CDC's criteria for MIS-C [7] . Compared to control (n=14), children with severe inflammation were more likely to present with dyspnea (72¢7% vs 28¢6%), vomiting (45¢5% vs. 7¢1%), and diarrhea (45¢5% vs. 21¢4%). White blood cell counts were comparable between the groups; however, patients with MIS-C have significant lymphopenia (11¢1% vs. 41¢8%). No difference was noted in platelets or liver function markers. Serum lactate dehydrogenase and D-dimer were higher in children with MIS-C (p<0¢05, details provided in Table 7) . Also, patients with MIS-C had lower expression of circulating CD16 + CD56 + natural killer cells. Imaging findings and treatments were comparable in MIS-C and non-MIS-C patients.

Over the last 6 months, there have been over 6¢4 million worldwide cases of SARS-CoV-2 infection and our knowledge of the disease and its epidemiologic and clinical characteristics continue to evolve [4]. However, since it was first reported in Wuhan city in December 2019, most studies have focused on symptomatic adults. In the presence of this rapidly emerging, novel infection, identification of clinical and laboratory characteristics in the pediatric population is essential to guide clinical care, predict disease severity, and determine prognosis. In this context, we performed the largest and most comprehensive systematic review of published studies involving pediatric patients with known COVID-19. Our systematic review summarized the clinical, laboratory and radiologic features of COVID-19 in neonates, children, and adolescents.

Our review also supports the findings by a recent systematic review by Castagnoli et al. [17] Their study included a total of 1,065 COVID-19 infected children and concluded that, by and large, the prognosis for children was excellent, demonstrated by only one death. Compared to that review and other COVID-19 pediatric systematic reviews, [18À21] this manuscript has several key advantages: (1) we summarize 131 studies that includes 7780 children from 26 different countries, (2) this report synthesizes underlying pediatric medical conditions and delineates bacterial and viral coinfections, (3) we quantitatively describe clinical symptoms and imaging findings, (4) herein, we conglomerate the mean and standard deviation of frequently used laboratory analytes in COVID-19 positive children, (5) our report presents antiviral therapies by specific agents, and (6) our systematic review offers a preliminary comparison of patients with/without MIS-C.

Although SARS-CoV-2 infection was first identified in China, the United States has now amassed the highest number of confirmed cases [18] . Calculations made on June 4th, 2020 from the COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University indicate that China has 4¢5% of total confirmed COVID-19 cases compared to the United States [4] . As expected, the most common vector for childhood infection is close contact to an affected family member or residing in an area with a high population of cases. Our findings align with the results of an April 2020 report by Dong et al, in which there was a clear trend that the disease spread rapidly from a Chinese province to surrounding provinces and cities in children from December to February [22] . Furthermore, Qiu and colleagues studied 36 pediatric COVID-19 positive patients in which ten patients (28%) were asymptomatic latent cases identified secondary to an adult family member who was infected, symptomatic, or traveled to an endemic area [23] . This lends concern that children, who may be asymptomatic, may play a role in community transmission of the virus. Continuous data presented as Mean § SD. NP-nasopharyngeal. Results from this systematic review echo findings describing milder symptoms in pediatric cases of SARS-CoV-2 infection [17, 21] . For instance, the most common clinical manifestations we found were fever (59¢1%), cough (55¢9%), rhinorrhea (20¢0%) and myalgia/fatigue (18¢7%). Unlike adults, children rarely progressed to severe upper respiratory symptoms requiring intensive care unit admission [24, 25] . Although transmission rates for SARS-CoV-2 are high, symptoms are less severe than SARS/Middle East Respiratory Syndrome (MERS) infection [26] . Serum inflammatory markers, specifically D-dimer, procalcitonin, creatine kinase, and interleukin-6, were consistently abnormal in the studies included in this review. Alterations to acute-phase infectionrelated biomarkers are corroborated in adult case series and metaanalyses [27, 28] . However, we must take caution when interpreting these outcomes and await more robust, longitudinal laboratory analyses. Again, these blood analyses are non-specific and may merely represent a pro-inflammatory state induced by the virus [26] .

In terms of imaging findings, we found that most patients had normal chest x-rays, a finding that is not surprising as most pediatric patients did not present with respiratory symptoms. Paralleling this review, a meta-analysis of CT features for COVID-19, showed that diffuse bilateral ground-glass opacities were the most common finding at all stages of disease [29, 30] . Despite these promising associations, it is important to consider that radiologic manifestations from various pathogens may have a similar impression and should be ruled out. Co-infections with other respiratory illnesses including influenza and mycoplasma were described in 72 patients. As elegantly described by Cox and colleagues, most fatalities from the 1918 influenza outbreak were secondary to bacterial infection [31] . Thus, future reports should not only describe coinfections but also detail pertinent negatives. At present, our study had a low rate of reporting the infectious workup (26¢7) of patients. Illustrating the importance, one of two patients that died in the study by Shekerdemian et al was due to gram negative sepsis in a child with comorbidities who developed end organ failure [32] .

Although most children have an uneventful course, a present concern is an inflammatory cascade in pediatric patients with COVID-19 [8, 9] . Clinical presentation includes an unremitting high fever, and includes systemic signs such as rash, conjunctivitis, and/or gastrointestinal symptoms. The case series of eight children from London required respiratory assistance, whether it was oxygen support (n=1), noninvasive ventilation (n=2) or intubation and mechanical ventilation (n=4) [8] . One patient was so ill that he required mechanical ventilation and extracorporeal membrane oxygenation. In addition, all required vasopressor support and demonstrated elevated levels of ferritin, D-dimers, troponin, procalcitonin, and C-reactive protein (CRP). Additionally, cardiac imaging showed ventricular dysfunction in five children. In another article, Italian investigators describe ten patients with MIS-C. Correspondingly, they describe patients manifesting with fever, diarrhea (n=6), and abnormal echocardiograms (n=6). Laboratory specifics showed elevated CRP, lymphopenia, thrombocytopenia, and elevated ferritin levels [9] .

We found evidence of MIS-C features in 11 children who also presented with fever (n=11), dyspnea (n=8), and diarrhea (n=6). According to Riphagen and Verdoni, lymphopenia was marked in our cohort of patients, as well as increased levels of lactate dehydrogenase, CRP and D-dimer [8, 9] . Despite low numbers we did observe an interesting lower level of CD16 + CD56 + natural killer (NK) cells in patients with MIS-C. Both lymphopenia and a reduced number/activity of NK cells in adults has correlated with a more severe COVID-19 disease progression [33À36] .

Little is known about the perinatal aspects of COVID-19, and there have been several reported cases of neonatal infection, suggesting a possible perinatal or vertical transmission during pregnancy [37] . However, in a report by Chen et al., all nine neonates born to COVID- Given that the mean (SD) in our pediatric population was 8.9 § 0.5 years we provide the lowest to highest numbers presented in children with a similar age range when possible (data from Nelson Textbook of Pediatrics 2019). *Gregory's Pediatric Anesthesia 2012 5 th edition.

y Mayo clinic laboratories. 19 positive mothers tested negative for the virus after cesarean delivery [38] . In another study by Zhang et al., 10 neonates from COVID-19 positive mother all tested negative for the infection [39] . Moreover, this is further supported by analysis of breast milk and placental pathologic specimens from COVID-19 positive mothers, which have returned negative for the virus [40, 41] . Lastly, vertical transmission was not observed with either SARS-CoV-1 or in MERS-CoV; [41] therefore, it is unlikely that maternal vertical transmission during third trimester occurs, or is likely very rare. However, from the limited data published, we cannot determine the consequences of SARS-CoV-2 infection in early pregnancy and if it can be transmitted to the fetus and hinder organ development, malformations, growth abnormalities, or even lead to premature labor or spontaneous abortions [42, 43] . Also, Dong et al communicated an alarming finding in which the proportion of severe and critical cases were higher in neonates when compared to the >16-year-old age group (10¢6% vs. 3¢0%) [44] . As a community, we must stay vigilant, practice social distancing, hand wash frequently, and be especially careful with our children who are at potentially higher risk for critical disease (e.g. multiple comorbidities, weakened immune systems, etc.).

There are several limitations to this review. First, many of the included studies were case reports or cases with low patient numbers.

Second, the level of evidence for all the studies was low. Next, we unified the laboratory data to mean and standard deviation. There are inherent issues when using averages including the impact of outliers. We did not include suspected cases, which would allow for a direct comparison of symptoms, labs, imaging, and outcome data. Of concern, many of the studies were incomplete and did not include a comprehensive picture of the patients. Future studies should not generalize data ("CBC was normal"), or categorize laboratory values (i.e., number of patients with elevated CRP), or group therapies (i.e., patient received "antiviral therapy"), or display aggregate data between adults and children. If feasible, divide the symptoms, laboratory markers, and imaging characteristics by children vs. adults. A better understanding of COVID-19 requires access to data, even if it is provided in the appendix or supplementary section of the article. In this way, we will be able to identify the best biomarkers that can stratify disease severity and potential short-and long-term outcomes. Another limitation, is that we had a small number of patients that fit the criteria for MIS-C. Reasons for the small number of patients includes a lack of reporting all of the signs, symptoms, and laboratory markers necessary to make the diagnosis (especially duration of fever). Missing information for laboratory markers (D-dimer, interleukins, and CD%) hinders our preliminary findings. Lastly, the Table 7 Comparison between covid-19 children with and without multisystem inflammatory syndrome in children (MIS-C).

MIS-C Data are presented as mean (SD) or median (IQR). Student's t test, Wilcoxon rank sum, or Fisher's exact was conducted as appropriate. * denotes limited data was in at least one group (D-dimer in MIS-C=3; Interleukins and CDs had 4 in non-MIS-C group vs. 4-5 in MIS-C).

literature focusing on COVID-19 is very dynamic and growing rapidly and we expect the rates, especially for MIS-C, of our outcomes to change.

Ansel Hoang-literature search, study design, data collection, data analysis, data interpretation, manuscript writing, risk of bias, tables. Kevin Chorath-literature search, study design, data collection, data interpretation, manuscript writing, risk of bias. Axel Moreira-literature search, study design, data collection, manuscript writing, data interpretation, risk of bias. Mary Evans-data collection, verifying data integrity, risk of bias. Finn Burmeister-Morton-data collection, verifying data integrity. Fiona Burmeister-data collection, verifying data integrity, risk of bias. Rija Naqvi-data collection, verifying data integrity, risk of bias. Matthew Petershack-data collection, risk of bias. Alvaro Moreira-literature search, study design, data collection, data analysis, data interpretation, manuscript writing, figure, tables, oversight.

None.

Creatine kinase (U/L) 77

Risk for transportation of coronavirus disease from Wuhan to other cities in china

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19

WHO declares covid-19 a pandemic

WHO. Coronavirus disease 2019 (COVID-19): situation report-28

COVID-19 in children: an epidemiology study from China

Resources for Emergency Health Professionals

Hyperinflammatory shock in children during COVID-19 pandemic Lancet2020

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Quality assessment tool for observational cohort and cross-sectional studies. Nhlbi. nih.gov/health-topics/study-quality-assessment-tools

Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols

Rules of evidence and clinical recommendations on the use of antithrombotic agents

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Coronavirus Disease 2019 in Children -United States, 2020. MMWR Morb Mortal Wkly Rep 2020February 12ÀApril 2

SARS-CoV-2 infection with gastrointestinal symptoms as the first manifestation in a neonate

Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review

Clinical manifestations of children with COVID-19: a systematic review

Clinical characteristics of COVID-19 infection in newborns and pediatrics: a systematic review

Characterisation of COVID-19 pandemic in paediatric age group: a systematic review and meta-analysis

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in china

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang. China Observat Cohort Study Lancet Infect Dis

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Middle east respiratory syndrome coronavirus in children

Elevated interleukin-6 and severe COVID-19: a metaanalysis

Clinical characteristics of 3,062 COVID-19 patients: a metaanalysis

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

A systematic meta-analysis of CT features of covid-19: lessons from radiology

Co-infections: potentially lethal and unexplored in COVID19

Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units

NKG2A and COVID-19: another brick in the wall

Immunology of COVID-19: current state of the science

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis

Possible vertical transmission of sars-cov-2 from an infected mother to her newborn

Clinical characteristics, and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Clinical characteristics of children with coronavirus disease 2019 in Hubei

Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know

Perinatal aspects on the covid-19 pandemic: a practical resource for perinatal-neonatal specialists

Epidemiology of COVID-19 among children in China

Funding sources: Parker B. Francis; Pilot grant 2R25-HL126140. Funding agencies had no role in the writing of the manuscript or the decision to submit.

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2020.100433.

